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Abstract
Major advances in genomics, cloning and chemistry will re-stock the dwindling supply of effective
antimicrobials and meet the threat of antibiotic resistance development.
Introduction and context
Almost all papers and reviews dealing with infectious
diseases stress that new classes of antibiotics are badly
needed to treat the increasing number of common and
emerging cases of infection due to antibiotic-resistant
organisms, be they bacteria, viruses or parasites. What
happened to the optimism of the late 1960s when the
then Surgeon General of the US announced ‘we can close
the book on infectious diseases’? For some years now it
has been clear that the situation with respect to the
treatment of common bacterial infections, especially in
hospitals, is poor, if not dire [1]. Physicians have a
diminishing armamentarium of antibiotics available for
clinical use; most of the older compounds are ineffective
against present-day resistant strains and reinforcements
are few and far between. Out-patient infections may still
be treatable with old standbys such as ampicillin and
related derivatives; however, in many of these cases
theinfectiousorganismisnotidentifiedandthecuremay
have beenmore aresultof naturalrecovery ofthe patient.
The few novel compounds available are reserved for last-
resort use and only in critical care units of hospitals.
If we are to continue with the current practices in the
treatment of infectious disease, new and reliable sources
of novel antimicrobials are badly needed for all types of
microbial diseases. Where will they come from? And
who will produce them? Much has been written by, and
about, the pharmaceutical industry focusing on the
difficulties of finding effective bioactive compounds; this
is coupled with comments on the poor profit return on
research in this area. Not surprisingly, the industry is
strongly disinclined to continue their efforts. I shall not
go into details of this pathetic ‘histoire’, enough has been
written on it by others closer to the problem [2].
However, in this commentary I will take issue with the
oft-repeated assertion that it is ‘hard’ to find new
compounds with the required therapeutic activity from
nature, the assumption being that Big Pharma has
exhaustively screened all of the available sources of
bioactive compounds and that slim pickings remain.
Emerging technological advances make it increasingly
clear that this stance is indefensible, as described below.
Major recent advances
If we assume that upwards of 100,000 different strains of
bacteria and fungi may have been screened for ther-
apeutic agents by the industry [3], this represents but a
fraction of the population of the microbial kingdoms (a
gram of soil may contain a thousand different bacterial
species). There are likely billions of antibiotic-producing
strains in the biosphere, each with the potential to
produce 10 times this number in terms of bioactive small
molecules with drug potential. This information comes
from two sources: firstly, more than 90% of microbes
cannot be grown under laboratory conditions; this
includes all possible environmental sources: marine,
terrestrial, endosymbionts, and so on. Secondly, exten-
sive genome sequencing over the past 10 years has
revealed that one of the most productive bacterial
sources of antibiotics and other therapeutic agents, the
streptomycetes, possesses the genetic capacity to make as
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so-called cryptic biosynthetic pathways are not expressed
(or are poorly expressed) under traditional fermentation
conditions, and their products have been missed because
of inadequate and insensitive screening processes. It is
safe to say that with increasing genomic analyses the
potential for the discovery of many new structural
entities will be enhanced considerably [5].
This treasure trove of bioactive compounds will not yield
its secrets and benefits easily. New methodology must be
developed to grow fastidious microbes in the laboratory
and creative approaches to the cloning and expression of
identified, but product-unknown, biosynthetic pathways
must be developed; new expression hosts and pathway
expression processes are essential for success. Another
major hurdle is the isolation, purification and structure
determination of the compounds produced by the
microbial hosts; traditional natural product chemistry
is almost a dark art, with very few skilled practitioners
worldwide. However, new methods of cell-based screen-
ing, compound isolation and structure determination are
coming on the scene; increasingly sensitive instrumenta-
tion may resolve other aspects of the discovery problem.
New types of high-throughput automated isolation
procedures with integrated spectroscopic approaches
to molecular analysis are becoming available and these
should eventually simplify and solve the issue of rapid
identification of novel chemistry [6]. At first these
approaches will be expensive, of course, but the need is
there and if the spirit is willing, with continual technical
advances, complementary analytical approaches (that
may be more affordable and user-friendly) will become
available. There is an excellent model to be found from
the revolution in DNA sequencing; it took several
billions of dollars to obtain a draft nucleotide sequence
of the human genome in 2000, 10 years later we are
speaking of $1000 genomes (or less!) [7]. More
importantly, for low molecular weight bioactives,
microbial genome sequences will soon be priced at $10
a shot and completed in a day. Antibiotic discovery will
start with the complete nucleotide sequence of a
biosynthetic pathway for an unknown compound, a
complete reverse of the traditional approach!
Of course, the identified pathways still have to be
converted into products, but prototypes for this type of
engineering are already established; even Escherichia coli
is considered a good candidate as expression host [8]. In
addition, the possibility of creating new types of
molecules by making hybrid biosynthetic pathways is a
field of investigation that will develop in parallel with
these approaches [9]. Engineering the amino acid
components of non-ribosomal peptides is yet another
method that shows promise for the production of non-
natural molecules in vivo [10].
To capitalize on the increasing availability of new classes
of small-molecule therapeutics, comparable advances in
high-throughput screening and testing of their diverse
bioactivities, using cell-based assays, will be essential,
and one can predict more extensive use of reliable insect
and worm models of human disease [11]. Imagine
screening thousands of microbial compounds against
hundreds of disease syndromes in microtiter plates!
Many of the necessary procedures are already in place but
they need to be made amenable to high-throughput
analysis. There is a huge world of bioactive small
molecules (the Parvome) waiting to be exploited for all
aspects of therapeutics!
An additional factor for success in antibiotic discovery
in the near future will come from a more comprehen-
sive understanding of natural microbial communities
and their interactions with their hosts, especially in
humans; our health is critically dependent on gut
microbiota. The rapidly increasing knowledge of this
type of dependency, when used in a predictive sense,
will surely identify more drug targets and more useful
drug leads. Rapidly advancing studies of the nature of
human and animal microbiomes are revealing extensive
roles of commensal microbes in the health and
maintenance of their complex hosts. Advances in this
field will surely reveal unanticipated drug targets for a
variety of afflictions; can we envisage a new branch of
industry ‘Micro Pharma’?
Future directions
All of the above technological advances (and more, such
as systems biologyand metabolicnetwork mapping) will
contribute to the means of producing newer generations
of antimicrobial agents. However, it is time to come back
down to earth. No matter what is done to revolutionise
the drug industry, it is necessary for the dispensers and
users of antibiotics to realize that bacteria are immortal;
all treatments should be carefully controlled so that we
can avoid or reduce the same problems with antibiotic
resistance development that have made so many good
drugs redundant in the recent past. And to finish with
stark reality, although the US Food and Drug Adminis-
tration rules, perhaps they also can mutate with new
solutions for health care needs.
To conclude, we must consider who will be responsible
for the implementation of these revolutionary develop-
ments in the process of drugdiscovery and development?
We cannot wait for the biopharmaceutical industry to do
this. Big Pharma is too hidebound by the tradition of
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on venture capital (a misnomer if ever there was one;
where is the adventure in modern venture capital?).
What is needed is a new drug discovery model; perhaps
university research combined with government grant
funding could lead to ways of enhancing the develop-
ment of early-stage discovery in academia. A number of
universities around the world have initiated pre-clinical,
pre-industry discovery groups with the goal of bridging
the freedom and originality of academic research with
the hard facts of drug development. This should be the
way of the future!
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